Clinical Trials Browser

Breast Neoplasms

Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

HER2 Negative Breast Cancer

Endometrial Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Advanced Breast Carcinoma

Low Grade Serous Ovarian Carcinoma

Recurrence, Endometrial Neoplasms

Estrogen Receptor-positive Breast Cancer

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Low-Grade Serous Ovarian Cancer

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Locoregional Recurrence

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Cancer Female

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Endometrial Stromal Tumors

Breast Neoplasms

Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HR Positive HER2 Negative Advanced Breast Cancer

Breast Neoplasms

Breast Cancer Metastatic

Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplastic Cells, Circulating

Breast Neoplasms

Endometrial Neoplasms

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Breast Neoplasms

Ovarian Neoplasms, Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Lobular

Clinical Trials

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

NAOMI

FASCINATE-N

CAMERAN

SELECT

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

I-SPY

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

ALEPRO

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

CHAMELEON

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

RaPhLRR

LaPemERLA

ADEPT

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

NeoMARS

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

CARABELA

FELINE

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

NELOPHER

BFR-ESS

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

ALPINE: Maintenance Letrozole/Abemaciclib

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Combined Immunotherapies in Metastatic ER+ Breast Cancer

ABIGAIL

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

POWER

ABC-SE

ARIADNE

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

METALLICA

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)